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Prostate cancer (PC) is the second most frequently diagnosed cancer and the second
leading cause of cancer deaths in man. The treatment of localized PC includes surgery or
radiation therapy. In case of relapse after a deﬁnitive treatment or in patients with locally
advanced or metastatic disease, the standard treatment includes the androgen-deprivation
therapy (ADT). By reducing the levels of testosterone and dihydrotestosterone under the
castration threshold, the ADT acts on the androgen receptor (AR), even if indirectly. The
effects of the ADT are usually temporary and nearly all patients, initially sensitive to the
androgen ablation therapy, have a disease progression after an 18–24 months medium
term.This is probably due to the selection of the cancer cell clones and to their acquisition of
critical somatic genome and epigenomic changes.This review aims to provide an overview
about the genetic and epigenetic alterations having a crucial role in the carcinogenesis and
in the disease progression toward the castration resistant PC. We focused on the role of
theAR, on its signaling cascade and on the clinical implications that the knowledge of these
aspects would have on hormonal therapy, on its failure and its toxicity.
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INTRODUCTION
Prostate cancer (PC) is the second most frequently diagnosed can-
cer and the second leading cause (the ﬁrst one is lung cancer) of
cancer deaths in man. The estimate of new diagnoses and deaths
from PC in 2012, in the United States, amounted to 241,740 and
28,170, respectively (American Cancer Society, 2012). In Italy, it
has been estimated that every year 23,518 new PCs are diagnosed;
deaths due to PC are 7,105 (AIRT, 1998–2002). PC incidence and
mortality displays geographic variation, with high rates of inci-
dence and mortality in the US and Western Europe, and low rates
in Asia (Makridakis et al., 1997; Figure 1).
Data show that mortality from PC is relatively lower compared
to the total number of yearly diagnosed cases. Therefore most
patients die with this disease rather than from it (Nelson et al.,
2008). The treatment of localized PC includes surgery or radiation
therapy. In cases of relapse after a deﬁnitive treatment or inpatients
with locally advanced (T3b to T4) or metastatic disease (N1 or
M1), the standard treatment includes the androgen-deprivation
therapy (ADT; Huggins and Hodges, 2002). The ADT aims to
reduce the circulating levels of testosterone around or below levels
present in castration (<50 ng/ml). The reason behind the use of
hormone therapy in the PC treatment is that the tumor growth is
initially dependent on androgens. Androgens stimulate the tumor
cells proliferation and inhibit their apoptosis. Conversely, ADT
reverses the equilibrium in favor of the second one (Figure 2).
The androgen deprivation (AD) can be achieved by the use of
LHRH analogs (medical castration) or bilateral orchiectomy (sur-
gical castration). Through the circulating levels of testosterone and
dihydrotestosterone (DHT) reduction, the ADT indirectly affects
the androgen receptor (AR), which represents the real target of
this therapy. The androgen biosynthesis consists in a multi-step
process taking place in man’s gonads and adrenals and in which
many enzymes are involved. Cytochrome P450c17α, with both
17α-hydroxylase and 17,20-lyase activity, has a key role among
these proteins (Figure 3).
The testosterone is the primary circulating androgen in man,
chieﬂy produced by Leydig cells in the testes and converted to
DHT in prostate cells by the enzyme 5-alpha-reductase (Figure 4;
Steers, 2001).
The androgenDHT ismore active having aﬁvefold higher afﬁn-
ity than testosterone for the AR. The androgen signal blockade
kills PC cells through the induction of a programed cellular death.
The effects of ADT are usually temporary and nearly all patients,
initially sensitive to the androgen ablation therapy, have a dis-
ease progression after a 18–24 months medium term (Crawford,
1992). This probably results from the cancer cell clones selection,
generated by the acquisition of critical somatic genome changes.
Castration resistant PC (CRPC) is a lethal form of PC deﬁned as
a tumor which develops in spite of very low levels of androgens
(below the threshold that deﬁnes castration). Preclinical investi-
gation has led to advances in the understanding of the molecular
basis of the CRPC. Various mechanisms have been proposed to
explain how the tumor becomes able to maintain an incentive to
grow in spite of very low serum levels of testosterone. This review
aims to provide an overview about the genetic and epigenetic alter-
ations having a crucial role in the carcinogenesis and in the disease
progression, toward a more aggressive phenotype (Ruijter et al.,
1999; Feldman and Feldman, 2001). In particular, we focused on
the role of the AR, on its signaling cascade and the on its clinical
implications that the knowledge of these aspects would have on
the hormonal therapy, on its failure and toxicity.
GENOMIC ALTERATIONS
Genomic alterations with a potential involvement in PC include
somatic mutations, gene deletions or ampliﬁcations, chromoso-
mal rearrangements. In the natural history of PC these alterations
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FIGURE 1 | Age-standardized rates (world) per 100,000 of PC in 2008 (data from Ferlay et al., 2010).
are probably accumulated over a period of several decades. The
ﬁrst studies on the molecular changes, with a potential crucial role
in the development of PC, have identiﬁed chromosomal abnor-
malities frequently reported in PC patients, such as the gain of
genetic material in 7p, 7q, 8q, and Xq and losses in 8p (Helcomb
et al., 2009), 10q, 13q, and 16q. Some studies have shown that a
chromosomal translocation involving TMPRSS2 (PSA-regulated
gene transmembrane protease, serine 2), an androgen-responsive
gene and a member of the ETS family of transcription factors
(ERG, ETV1, ETV4, or ETV5) is present in over 60% of localized
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FIGURE 2 |Androgen-deprivation therapy (ADT) effect on proliferation/
apoptosis PC cells: androgens stimulate the tumor cells proliferation
and inhibit their apoptosis. ADT reverses the equilibrium in favor of the
apoptosis.
and metastatic prostate tumors and in 20% of PIN (Tomlins et al.,
2005). ETS proteins cooperate with other transcription factors in
the regulation of various cellular functions such as proliferation,
differentiation, angiogenesis, apoptosis, and carcinogenesis. The
ERGgene is themost common fusion partnerwith TMPRSS2. The
incidence of the TMPRSS2–ERG fusion is almost 60% in PC. Both
FIGURE 4 | 5-alpha-reductase activity in prostate cells.
genes are localized on chromosome 21q22 and the fusion takes
place by an interstitial deletion. Translocations involving other
ETS family members occur rarely. Seventeen different TMPRSS2–
ERG fusions, involving different regions of the TMPRSS and the
ERG, have been identiﬁed. Eight of these fusions do not encode
functioning ERGproteins for the introduction of a premature stop
codon. Nine give rise to functional fusionproducts: two encode the
normal ERG protein, six truncated ERG proteins, and one is a new
protein resulting from the TMPRSS2 and the ERG fusion. The
FIGURE 3 | Steroid biosynthesis.
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biological consequence of these different products is unknown.
The TMPRSS–ERG translocation is considered an early event in
the development of PC; it is not present in prostate benign lesions
or hyperplasia. However, this is probably not the initial event as
it is observed only in 20% of the PIN and it does not seem to
have a direct role in the progression to adenocarcinoma. These
data suggest that additional genetic mutations must occur. Aber-
rations were also identiﬁed in signal pathways of growth factors
(NKX3.1, PTEN, c-MYC, and p27) and in the AR axis as determi-
nants of the cancer cell phenotype. The LOH of 8p21.2 is found in
60% of the PIN and 85% of PC. The transcription factor NKX3.1
AR-regulated, whose normal function is to facilitate the terminal
differentiation of prostatic epithelial cells, maps in this location. It
has been suggested that theNKX3.1 is a gatekeeper tumor suppres-
sor gene, similar to theAPC in the colon cancer, to theVHL in renal
clear cell carcinoma and to the RB in retinoblastoma. In contrast to
peculiar tumor suppressor genes, however, allele of theNKX3.1has
not changed and the loss of heterozygosity determines a reduction
of protein levels. The ampliﬁcation of chromosome 8q24 associ-
ated to the over-expressionof the transcription factorMYC ismore
frequently observed in PIN and in localized or metastatic PC. The
decrease of p27, a cell cycle inhibitor, is correlated with an increase
in histological grade of PC and with the risk of relapse. The LOH
12q12-13 containing p27 is present in 20% of localized disease
cases and in approximately 50% of metastatic disease (Mackinnon
et al., 2009). Also, single-nucleotide polymorphisms (SNPs) in key
genes have been hypothesized to be associated with PC risk, out-
come, and responsiveness to therapies. With respect to this topic,
a meta-analysis based on 38 studies involving 34,782 cases of PC
and 38,626 controls, suggested that the SNP of the CYP17 gene,
rs743572, may be signiﬁcantly associated with the risk of PC in
the Black population (but not in Caucasian and Asian; Wang et al.,
2011). Wright et al. (2010) afﬁrmed that men with genetic vari-
ants in the CYP17 may differ in responsiveness to drugs from the
wild-type gene carriers. This may have critical effects in regulating
response of PC to the new CYP17 inhibitors like the Abiraterone
acetate.
EPIGENOMIC ALTERATIONS
Epigenetic changes are all the heritable changes in gene expres-
sion not resulting by alterations in the DNA sequence (Berger
et al., 2009). The well-known epigenetic mechanisms are DNA
methylation, changes to chromatin and alterations of microR-
NAs expression. Considerable evidences exist that a global DNA
hypomethylation occurs late in PC contributing to the disease pro-
gression by promoting genomic instability (Chin et al., 2011). The
inactivation of speciﬁc genes, caused by silencing their transcrip-
tion through epigenetic alterations, is largely known as one of
the mechanisms which can contribute to carcinogenesis. Among
these epigenetic alterations in PC, the aberrant methylation of
DNA in the promoter region of some genes (like GSTP – pi-class
glutathione S-transferase) is a signiﬁcant event (Lee et al., 1994).
The somatic inactivation of the GSTP, which is a gene involved in
detoxiﬁcation, is the result of an aberrant methylation (hyperme-
thylation) of CpG islands located in the gene promoter. As a result
of this alteration the cells are more prone to accumulate addi-
tional mutations. This event seems to be involved in an early stage
of the prostatic carcinogenesis: it is present in 70% of high-grade
PIN and in more than 90% of adenocarcinomas (Nakayama et al.,
2003; Kang et al., 2004). Li et al. (2001) observed that the degree
of hypermethylation of E-cadherin gene (a gene in maintenance
of normal cell architecture involved) in PC tissue was correlated
with the pathological stage. They found an hypermethylation of E-
cadherin gene promoter into the 30% of low-grade and the 70% of
high-grade tumor tissues, respectively. Furthermore, hypermethy-
lation of the p16 gene promoter results in a proliferative advantage
of the cell clone so modiﬁed, with obvious implications, both in
carcinogenesis and in the disease progression (Jarrard et al., 1997;
Gu et al., 1998). In about 66% of PC the expression of the PTEN,
an inhibitor of the PI3K/Akt pathway, is reduced or absent, with
consequent activation of the PTEN/AKT/mTOR pathway. PTEN
loss of function can result from deletion, mutation or epigenetic
gene silencing. The PTEN epigenetic transcription silencing is
often consequence of the CpG islands methylation located in its
promoter region and would have a role in disease progression
(Cairns et al., 1997; Suzuki et al., 1998). In some PC, the DNA
hypermethylation could be also involved in the regulation of the
AR expression. Suzuki et al. (2003) data showed that in 30% of
hormone-refractory PC, the expression of the AR may be lost
as a result of the AR promoter gene hypermethylation. Similarly
the hypomethylation and consequent upregulation of genes like
heparanase, urokinase may contribute to tumor cell invasion and
metastasis (Hulett et al., 1999; Pakneshan et al., 2003). More exam-
ples of genes frequently silenced in PC are the APC, the MGMT,
and the MDR1 (Kang et al., 2004).
CASTRATION RESISTANT PROSTATE CANCER AND AR
The issue of androgen independence has been recently reviewed
in light of the new knowledge achieved, so much so that today
the term of resistance to castration is preferred. It is known that
in the process of PC progression, the AR signaling axis maintains
a decisive role: PC cells, once become resistant to castration, can
evade the ADT cell growth inhibition and continue to express
androgens-regulated genes even with castration serum levels of
androgens. This should be partly explained by genetic alterations
on the AR. As demonstrated in literature, AR alterations are
observed in more than 50% of metastatic PC cases and tend to
be rare in limited disease (Marcelli et al., 2000). It is yet unclear
when the tumor acquires genetic alterations leading to castration
resistance. While some studies suggest that tumor acquires these
genetic alterations regardless of the ADT, other data highlight that
the ADT would exert selective pressure on tumor cells. In this
way the ADT would select cell clones able to grow independently
from androgens, thanks to AR mutations (Taplin et al., 1995). The
AR is a nuclear transcription factor whose gene belongs to the
steroid–thyroid–retinoid nuclear receptor super-family. The AR
gene is located on the X chromosome and contains eight exons.
It encodes a protein of 919 amino acids. The AR is composed
of four different domains: the N-terminal domain (NTD), the
deoxyribonucleic acid-binding domain (DBD), the hinge region,
and the ligand-binding domain (LBD; Lonergan and Tindall,
2011). AR aberrations correlated to the long-term failure of the
ADT include the AR ampliﬁcation/over-expression, the alterna-
tive source of androgens, the mutated AR or promiscuous AR, the
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over-expression of AR co-regulators, the AR activation by CK or
growth factors. Nevertheless, the AR continues to be expressed
even in disease advanced stages, regardless sensitivity to hormonal
therapy (van der Kast et al., 1991; Hobisch et al., 1995).
AR AMPLIFICATION/OVER-EXPRESSION
The ampliﬁcation of the AR gene has been associated with
endocrine therapy failure. In a Finnish study on 54 patients, this
speciﬁc alteration was found in about 30% of locally recurrent
or metastatic hormone-refractory tumors, while absent in the
untreated ones. Koivisto et al. (1997) concluded that AR ampli-
ﬁcations occurs exclusively during the disease progression after
the ADT and it is more frequent in tumors with an initial good
response to the hormone therapy. Indeed, tumor cells in this case
would be more critically dependent on androgen than in patients
primarily resistant to ADT. Also, recurrent tumors with the AR
gene ampliﬁcation treated with a ﬁrst-line hormonal monother-
apy, could beneﬁt from a second-line combined androgen block-
ade, more than patients without this AR alteration, although this
does not mean a gain in survival (Palmberg et al., 2000). Gregory
et al. (2004) also conﬁrms that the basis of castration resistance
may consist in an hypersensitivity of the AR, resulting from its
over-expression, increased stability and intranuclear localization.
ALTERNATIVE SOURCE OF ANDROGENS
In spite of extremely low levels of circulating androgens, the CRPC
progression remains dependent on the androgen-driven activity
and PC cells keep the AR pathway active in different ways. An
hypothesis standing to explain this observation is that alternative
sources of androgenic steroids exist. Pioneer works, conﬁrmed by
recent researches in this area, indicated that intraprostatic amount
of testosterone and DHT remains moderately high despite their
castration serum levels (Liu et al., 1985; Labrie, 2004; Titus et al.,
2005). Locke et al. (2008) hypothesized that androgens de novo
synthesized within prostatic tumor tissue may drive the CRPC
progression in the absence of testicular androgens. Also they argue
that some enzymes necessary for androgens synthesis (SRD5A1,
RDH5,ARK1C1,2,3) are up-regulated inPCcells during theCRPC
progression. Montgomery et al. (2008) remarked this theory show-
ing that all the enzymes involved in the biosynthesis of testosterone
and DHT were expressed in the majority of metastatic CRPC
examined in his study. This would explain how the decrease of
DHT in prostate tissue after the ADT may not be proportional
to decreased levels of circulating testosterone (60 vs. 95% respec-
tively; Labrie et al., 1986). What also appears to be assumed is that
the adrenal steroids peripheral conversion may be sufﬁcient to the
maintain androgen signal, resulting in the tumor growth and in
the ADT failure. This is the rationale behind the use of the com-
bination therapy with antiandrogen plus LHRH analog and the
basis for use of CYP17 inhibitors like ketoconazole (use limited by
its toxicity; Trachtenberg and Pont, 1984), recently the abiraterone
acetate (a potent inhibitor of the CYP17α-hydroxylase; De Bono
et al., 2011) and Orteronel (TAK-700; Yamaoka et al., 2012).
MUTATED OR PROMISCUOUS AR
Androgen receptor genetic changes leading to aberrant function-
ing of the AR pathway may underlie the development of resistance
to castration, allowing tumor cells to avoid the normal stimuli to
growth. Largely, we are talking about somatic mutations in the AR
gene, resulting in an increase of the potential ligands which bind
and activate the AR receptor. The AR somatic mutation would
include missense mutations like T877A and L701H. The T877A
missense mutation has been described for the ﬁrst time in LNCaP
cell lines and affects the LBD of the AR. This alteration allows to
ligands different from testosterone and DHT, such as progestins,
estrogens, and antiandrogens to activate the AR. This may pro-
vide a molecular basis to “withdrawal syndrome” (i.e., patients
treated with maximal androgen blockade, can beneﬁt from the
stop of antiandrogen (Kelly and Scher, 1993; Small and Srinivas,
1995). Zhao et al. (2000) described how the L701H mutation in
conjunction with the T877A mutation of the LBD of theAR, could
involve stimulating mutant cells growth by glucocorticoids (corti-
sone, cortisol). This may have important implications in clinical
practice when you choose the glucocorticoid to be used in therapy.
OVER-EXPRESSION OF AR CO-REGULATORS
The AR activates its target gene transcription in response to
the androgen stimulus. Its transactivation activities are modu-
lated by co-regulators. Some evidences support the importance
of co-regulators in the carcinogenesis and the development of
hormone-resistance in PC. AR co-regulators consist of almost 200
proteins able to enhance (co-activators) or repress (co-repressors)
the transcriptional activity of the AR. Genes mutation or the
aberrant expression of this molecules may participate in PC
progression (Gao et al., 2002). Several ﬁndings suggest that the
NCOA2 gene (a nuclear receptor co-activator) would play the role
of the potential oncogene in PC. Taylor et al. (2010) hypothe-
sized that its ampliﬁcation or mutation in primary and metastatic
PC enhances the androgen-dependent AR transcriptional activity.
The steroid receptor co-activator (SRC) family includes the SRC-1,
the SRC-2, and the SRC-3. Literature shows that the SRC-1 is over-
expressed in ADT-refractory PCs. Gregory et al. (2004) found that
the SRC-2 is also over-expressed in recurrent PCs. This changemay
contribute to PC relapse after endocrine therapy. There is no clear
evidence about the possible roles of the SRC-3 in prostate tumor
development and progression. The steroid receptor RNA activator
(SRA) is another co-activator for steroid receptorswhich functions
as a RNA transcript in a ribonucleoprotein complex containing the
SRC-1. Kawashima et al. (2002) showed that the SRA expression
is higher in androgen-independent PC cell lines (PC-3) compared
to the androgen-dependent ones (DU-145, LNCaP). The AR-
associated protein ARA70 can interact with the AR and modulate
its transcriptional activity in response to the androgens stimu-
lation. It must also be reported that the ARA70 could facilitate
the agonist activity of antiandrogens like bicalutamide (Miyamoto
et al., 1998). In normal prostatic epithelium the ARA70 is highly
expressed, while studies showed that the ARA70 expression was
decreased or suppressed by methylation in androgen-dependent
PC cell lines (DU145). Its expression seems to be regulated by both
ER and AR in PC cells (Tekur et al., 2001).
THE AR ACTIVATION BY CK AND GROWTH FACTORS
The possibility of a cross-talk between the AR pathway and intra-
cellular signaling cascades activated by IGF-1, KGF, and EGF,
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leading to transcription of androgen controlled genes, in the
absence of the ligand exists (Culig et al., 1994). The ErbB or
HER receptor network is frequently alterated in solid tumors.
The HER kinase family includes: the epidermal growth fac-
tor receptor (EGFR or ErbB1), the human epidermal growth
factor receptor 2 (HER2), the ErbB3 (HER3), and the ErbB4
(HER4). The HER2 is the only one in a ﬁxed open conforma-
tion, other members need to bind to the ligand to form active
dimer instead (Solit and Rosen, 2007). In breast cancers, the
ErbB2 over-expression correlates with estrogen independence.
In the ErbB2 over-expressed breast cancers therapy the anti-
HER2 monoclonal antibody, trastuzumab (Herceptin) can be
used. Similar to the breast cancer case, or even in PC (Sig-
noretti et al., 2000), it may exist a connection between the
over-expression of the HER2/neu (also known as ErbB2) and
the progression to castrate resistant disease. The activation of
the HER2 signaling cascade may lead to constitutive activation
of the AR (Craft et al., 1999; Yeh et al., 1999). Studies sug-
gest that the ErbB receptor activation may be important in the
growth and in the survival of both androgen-dependent and
androgen-independent PC (Agus et al., 2002). In particular, the
ErbB2–ErbB3 signaling has been implicated in enhancing the
AR signaling through modulation of its transcriptional activ-
ity and its degradation in the presence of low androgen levels
(Mellinghoff et al., 2004). Wen et al. (2000) showed in LNCaP
cells that the HER2/neu activates Akt (protein kinase B) and in
this way promotes the PC cells survival and growth in absence
of androgens. These conditions may open new ways to PC ther-
apy. However, when trastuzumab (Lara et al., 2004; Ziada et al.,
2004) and pertuzumab (a second generation of anti-HER2 mono-
clonal antibody; De Bono et al., 2007), as well as the EGFR tyrosine
kinase inhibitors (TKIs) geﬁtinib (Canil et al., 2005) and erlotinib
(Gravis et al., 2006) have been tested in PC, it was observed a
non-signiﬁcant single-agent activity. These results suggest that
these targets may be of secondary importance or of primary
importance only in few cases of PC. According to the disap-
pointing results obtained by the single use of these molecules,
some researchers attempted to test them in combination. These
therapeutic strategies aim to get the return of prostatic can-
cer cells to the androgen sensibility. Distinct phase II studies,
show that three EGFR inhibitors have been combined with doc-
etaxel. In single-arm studies of the geﬁtinib or erlotinib, PSA
and tumor responses were modest, although the erlotinib showed
favorable survival (24.6 months) with increased toxicity (Gross
et al., 2007; Salzberg et al., 2007). Recent evidences also sug-
gest that the HER-2 expression confers an increased risk of CNS
metastases in the metastatic CRPC (Gernone et al., 2011). Other
factors not directly related to the AR are certainly involved in the
carcinogenesis and progression of PC. Data from some studies
point to the potential role of proteins involved in the regula-
tion of vascular permeability and endothelial proliferation. In
2006, a study shown that the endocrine gland-derived vascular
endothelial growth factor/prokineticin 1 and 2 (EG-VEGF/PK1
and 2) and their receptors were expressed after the transi-
tion from benign to malignant prostatic glandular epithelium
and that their levels increased with increasing histological grade
(Pasquali et al., 2006).
TREATMENT FOR CASTRATION-RESISTANT
PROSTATE CANCER
Currently, chemotherapy represents one of the possible treatment
options in the setting of the CRPC, providing modest survival
and palliative beneﬁts. However, many other therapeutic options
are now available. With the FDA approval of Docetaxel in 2004
prospects on the therapeutic possibilities for this type of cancer
has gradually expanded. Docetaxel-based chemotherapy (given
every 3 weeks at a dose of 75 mg/m2 along with a corticosteroid)
as standard treatment in the CRPC is based on the survival advan-
tage (approximately 3 months in median OS when compared with
mitoxantrone andprednisone) observed in two independent phase
III studies (TAX 327 trial and SWOG 99-16 trial). However, most
men treated with this drug experienced progression of their dis-
ease within 1 year from the start of chemotherapy. Between 2010
and 2011 the cabazitaxel, the sipuleucel-T and the abiraterone
acetate were also approved by the FDA for treatment of metastatic
CRPC. In addition, a novel new bone-targeting monoclonal anti-
body, denosumab (Xgeva), and an LHRH antagonist, degarelix
(Firmagon), have been introduced into clinical practice. Cabazi-
taxel is a microtubule inhibitor approved by FDA for the treatment
of patients with CRPC progressed after docetaxel. Cabazitaxel, in a
phase III multicenter study, in which it was compared with mitox-
antrone, showed a statistically signiﬁcant advantage in terms of
median overall survival (15.1 vs. 12.7) and PFS (2.8 vs. 1.4; De
Bono et al., 2010). Also Abiraterone, in a phase III study, has
been shown to improve the outcome of men progressing dur-
ing or after a docetaxel-based chemotherapy treatment in which
it prolonged the patients median survival to 4 months if com-
pared to placebo (De Bono et al., 2011). Abiraterone (a potent
and irreversible inhibitor of the CYP17A) is designed to treat the
CRPC by inhibiting the production of androgen in the testis, in
the adrenal glands, and in prostate tumor itself. Since there are no
head-to-head comparisons to guide us in choosing between these
two drugs, largely, patients for these therapies are selected accord-
ing to the different side effect proﬁle of these agents. One trial is
currently ongoing looking at the comparison of abiraterone plus
prednisone vs. placebo and prednisone in asymptomatic or mildly
symptomatic metastatic CRPC who have not received chemother-
apy. The Sipuleucel-T is an autologous cellular immunological
agent, obtained by leukapheresis and cultured (activated) with a
recombinant human protein (PAP-GM-CSF) consisting of pro-
static acid phosphatase linked to the granulocyte-macrophage
colony-stimulating factor, that shown to improve survival in min-
imally symptomatic patients. The Sipuleucel-T is thought to work
through APCs to stimulate the T cell immune response targeted
against thePAP,an antigen that is highly expressed inmost PCcells.
The mechanism for immunotherapy of PC, in general, is that can-
cer cells contain antigens of the prostate that can be recognized
by the immune system (through the APC and T cells) allowing
a selective killing of PC cells. T cells respond to small peptides
derived from intracellular proteins and are present on specialized
molecules on the surface of cancer cells. PC cells can be recog-
nized by virtue of containing new proteins, formed as a result
of mutations in somatic gene translocations, or to express pro-
teins lineage, representing differentiation prostate cells (Kantoff
et al., 2010a). Today new agents are being evaluated for men with
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metastatic CRPC in both ﬁrst-line (in combination with doc-
etaxel) and second-line treatment (in men progressing during
or after treatment with docetaxel). Phase III clinical studies are
ongoing on molecules with different targets: the androgen sig-
naling pathway (MDV3100, Scher et al., 2010; TAK-700, Dreicer
et al., 2010) has demonstrated signiﬁcant activity in phase I and II
studies), immunoregulatory pathways (Ipilimumab, the Prostvac-
VF-Tricom (Kantoff et al., 2010b), the Src (dasatinib; Araujo et al.,
2009), the Met (cabozantinib), and the angiogenesis (aﬂibercept;
Isambert et al., 2008, tasquinimod). Recently, attention has been
paid to the possibility of radioimmunotherapy (RIT) use in PC.
The prostate-speciﬁc membrane antigen (PSMA) is an integral
cell-surface membrane protein and an ideal target for mono-
clonal antibody therapy. The anti-PSMA monoclonal antibody –
radionuclide labeled (J591) has been studied in phase I and II stud-
ies. The most common radionuclides used have been 90-Yttrium
and 177-Lutetium. This trials seem to suggest that the radiolabeled
J591 has antitumor activity and is well tolerated. Phase I trial on
chemotherapy and RIT combination is also ongoing (Milowsky
et al., 2004; Bander et al., 2005; Tagawa et al., 2008, 2010). How-
ever, resistance to the ﬁrst-line chemotherapy occurs, inevitably,
even in patients who initially responded. Studies were designed in
order to overcome this obstacle in different ways. Some researchers
attempted associating docetaxel to amolecule able to interferewith
one or more mechanisms of chemotherapy resistance. The aim is
to improve the efﬁciency of a well-known cytotoxic agent to carry
out its task. On the basis of encouraging results of a phase II
trial, Chi et al. (2009) employed this strategy in a phase III study
using the antisense oligonucleotide: the custirsen (OGX-011). Evi-
dences in literature also indicate that tumor microenvironment
may be critically implicate in PC therapy resistance. In partic-
ular angiogenic growth factors like vascular endothelial growth
factor (VEGF) may have a crucial role in mechanisms guiding
bone metastatization and disease progression. So recently atten-
tion has been paid to the use of docetaxel in conjunction with
stroma-targeting molecules.
CONCLUSION
Nowadays treatment options available for the CRPC are many
and new questions emerge. First, how these new drugs have to
be administered in clinical practice. In the era of the personalized
cancer therapies, the deep knowledge of underlying mechanisms
of the castration resistance of PC has become a topic of primary
importance. Research in this ﬁeld aims to obtain the tools in order
to choose the most effective and less toxic therapy for each patient.
This is more evident if we think about the impact of the hor-
mone therapy on patients with PC quality life. In this way risks
and beneﬁts, ratio of a single therapy, have a greater signiﬁcance.
New biomarkers able to predict which patients may really beneﬁt
from a speciﬁc therapy without being exposed to an unneces-
sary toxicity, are required. For the future it should be possible to
understand the genetic background of our patients with regard to
some critical enzymes which could inﬂuence both response and
resistance to drugs, before starting a speciﬁc therapy. This chance
couldmake it really feasible to personalize the therapy in individual
patients.
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